Data, Precision, and Confidence are Redefining CX in Pharma

Authored by: Karan Raje, Partner, Inizio Ignite, Putnam, Nick Fletcher, Consulting Director, Inizio Ignite, Vynamic, Mariel Metcalfe Director, Inizio Ignite, Research Partnership & Craig Galloway, Head of Global Client Partnerships, Inizio Ignite, STEM

Pharmaceutical customer experience is being redefined by what data, predictive analytics and AI are now making possible. While the ambition to create more connected customer experiences is not new, these capabilities give pharma a better understanding of when, where, and how to engage clinicians and patients.

In this article, we explore what it means to move beyond fixed models of CX towards a more adaptive approach: one that starts with customer need, uses data and AI to guide engagement, and focuses less on delivering more content and more on helping customers make sense of it. This isn’t about transforming everything at once. It’s about measuring impact, learning what works, and scaling what delivers value.

Confidence, not content

HCPs aren’t suffering from a scarcity of information; they are overwhelmed by fragmented digital platforms, uncurated data feeds, and promotional noise, which does not always support informed decision-making where time is critical for patients. At the same time, the information itself is becoming more complex. Advances in areas such as biologics, precision medicine and biomarker-led therapies can require HCPs to interpret unfamiliar mechanisms of action, patient selection criteria, and toxicity profiles. Access to information is one factor; HCPs also need to determine what is relevant, credible, and applicable to the patient in front of them.  As digital tools and AI discovery engines, such as OpenEvidence, become part of daily practice, HCPs may enter clinical conversation better informed and with faster access to information about trial data and treatment protocols.

With more information readily available, the value is no longer in simply providing it. Pharma can play a greater role in helping HCPs identify what is relevant, credible, and applicable to their patients. AI can summarize information quickly, but that does not necessarily make it reliable. High-stakes treatment decisions require verification against peer-reviewed evidence, clinical guidelines, and trusted expert dialogue. For field teams, that may mean helping HCPs digest information they have found through AI, understanding its limitations and knowing when to check it against trusted advice.

For pharma, that means starting with what the customer needs and stripping back activity that no longer serves that need and focusing on what genuinely adds value. Ultimately, that means helping HCPs answer the question that matters: what is the right therapy for the right patient at the right time?

Pharma is also witnessing the “retailization” of healthcare as clinicians face seamlessly connected digital touchpoints from brands like Amazon in their personal lives and expect the same in their professional environment. Similarly, the relationship with patients is becoming more direct, particularly in areas such as GLP-1s, where consumer-led models of accessing treatment and support are emerging. Those expectations increasingly carry over into healthcare, whether pharma is engaging with an HCP or directly with a patient.

Patients themselves are becoming more actively engaged in how they navigate healthcare. They may be using large language models (LLMs) alongside conversations with HCPs, accessing medicines through employers or direct models, comparing options outside traditional healthcare channels, and overall, making their own decisions. Much of this activity sits outside the channel’s pharma has traditionally relied on to understand patient behavior.

Getting closer to how people actually make those decisions can help fill the gap: where they are looking for information, who and what they can trust, and what influences the choices they make.

Precision over novelty

Understanding how a customer might engage with information is only one step in the customer journey. The bigger shift is in how much pharma can now understand about that journey, and how quickly teams can act on it. Advances in data, analytics, and AI make it possible to connect different sources of information, including quantitative, behavioral, and attitudinal data, as well as previous interactions. Instead of relying mainly on delayed feedback, teams can paint a more current picture of customer needs and see how previous engagement has worked. That can inform both what happens next and whether a human or digital interaction makes more sense.

Predictive patient finding

A practical example is predictive patient identification. In one recent engagement involving a rare, biomarker-driven cancer, eligible patients could emerge across a wide range of care settings rather than primarily within established high-volume treatment centers. The challenge was compounded by a treatment window of as little as 11 days: if the right HCP was not aware of the therapy, or the patient was not connected to the right specialist quickly enough, that opportunity could be lost once chemotherapy began.

A predictive approach that combines traditional targeting inputs with AI and machine-learning signals can help teams anticipate where an eligible patient may emerge next. Rather than relying primarily on where similar patients have historically been treated, field teams could use those signals to reprioritize territories and focus engagement where it can support faster identification, referral and treatment consideration within the available window.

The same approach could have relevance in other rare, biomarker-driven diseases, particularly where patient populations are small, care pathways are dispersed, and treatment windows are narrow.

More precise, adaptive engagement

Richer data and predictive signals are giving pharma a better understanding of what different customers need and when those needs change – which changes what personalization can look like. Engagement can be tailored more closely to the asset, market and individual customer, rather than relying on broader assumptions about what is likely to work. Teams can adjust as they learn from each interaction and, in some cases, identify a need or question before it surfaces in conversation.

Field team value

Field teams have been becoming more consultative for some time, but the rise of AI as a primary provider of information makes that consultative role more important. If digital channels take on more routine information gathering, MSLs and reps have more room to focus on the parts of an interaction that require clinical context, communication, and judgement. As therapies themselves become more complex, this can include helping HCPs navigate novel mechanisms of action, biomarker data, patient selection, and toxicity consideration. Simply providing information becomes less useful when an HCP can retrieve it elsewhere. Interpreting it in the context of a particular clinical question is harder to replace. In some settings, that also means understanding more of the context around clinical decisions, including patient pathways, local priorities, and practical barriers.

Prioritizing time spent

But not every interaction requires that level of human involvement. When there is no straightforward answer, when the consequences of a decision are significant, or when a situation falls outside the usual journey are all situations where conversation and judgement matter. Elsewhere, digital interaction may be enough. The question is not which channel should replace the other, but which one fits the need.

Rather than field teams spending more time with familiar or already engaged HCPs, data can help identify where human interaction has a greater chance of making a difference.

The adoption ladder can still help guide those choices. A HCP who is already confident and experienced with a treatment may need a different type of interaction from someone who has unresolved questions or concerns. Richer and more current signals can give teams a better indication of where a HCP sits on that journey, what questions remain, and whether a field interaction is warranted.

For some HCPs, that may mean further targeted information or digital support. For others, a conversation with a field team or peer may be more useful in addressing specific clinical questions or concerns.

Strategy into action

The challenge is turning these capabilities into something that actually works in practice. Large pharma organizations still have silos across commercial, medical affairs, data, analytics, and technology, which can make a connected customer experience harder to deliver. Trying to change everything at once is unlikely to solve that.

AI will not transform customer experience overnight. Progress is more likely to come from targeted implementation, measuring what works and building from there. Technology can improve the speed and precision of engagement, while human expertise is focused where it adds the greatest value.

Pilot and demonstrate

A more practical approach is to start with a specific therapeutic area, asset, or a market where there is clear customer need. Teams can then use this pilot to test predictive targeting, refine the sharing of integrated insights, and measure behavioral outcomes. What works can then be refined and applied elsewhere, rather than assuming the same model will work across every asset or market.

This matters as pharma faces growing pressure to demonstrate the return on customer engagement. That makes measurement an integral part of the design, rather than something added at the end. Teams need to know which activities are changing behavior or improving outcomes, and which are simply generating more activity and cost. That could mean looking beyond the number of interactions to understand whether an engagement addressed a knowledge gap, changed confidence, or led to a different action.

Prove, iterate, and scale

The fundamentals of good customer experience have not changed. Understanding the customers, having good data, and creating valuable human interactions have always mattered. What has changed is the speed and level of precision with which pharma can act on them.

Data and AI can help teams make better choices about who to engage, what they need, where human interaction will add value and what to do next. Just as importantly, they can help teams learn from those choices and adjust where needed. The opportunity is to reduce activity that is not adding enough value, focus investment where it is having an impact, and scale what works.

Key takeaways

• HCPs do not need more information; they need help filtering and identifying what is relevant and credible to their needs.
• AI and advanced analytics can make targeting more precise, using richer data and predictive signals to help teams identify where engagement may have the greatest value and adapt as circumstances change. In some settings, this can support earlier patient identification and help HCPs connect eligible patients with appropriate treatment pathways sooner.
• As AI takes on more informational and routine work, the value of field teams increasingly lies in interpretation, judgement and navigating complexity or ambiguity. Human interaction can then be focused on where it has the greatest potential to make a difference.
• Success needs to be measured by what engagement achieves; not simply how much activity takes place. Better measurements can help teams understand what is changing behavior, reduce lower value activity and invest more selectively.
• Modernization does not need to happen all at once. Starting with a specific therapeutic area, assets or markets allow teams to test an approach, demonstrate its value, learn what works and scale from there.

Inizio Ignite unites insights, strategy and transformation to spark the future of health. Explore our solutions here.